- Vascular Biogenics Ltd (NASDAQ: VBLT) announced positive results of the pre-specified interim analysis of the Phase 3 OVAL study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer.
- VB-111 (ofranergene obadenovec) is an anti-cancer gene-therapy.
- The data was published online in Gynecologic Oncology.
- The analysis showed a CA-125 (validated biomarker) response rate of 58% or higher in evaluable patients in the VB-111 treatment arm.
- In patients who had a post-dosing fever, a marker for VB-111 treatment, the response rate was 69%.
- Recently an independent Data Safety Monitoring Committee found no safety issues with the Phase 3 trial and recommended its continuation.
- Price Action: VBLT shares are trading higher by 7.6% at $1.98 in premarket trading on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
